Edison Investment Research - Cantargia AB (CANTA) Cantargia - Encouraging data for nadunolimab in CANFOUR

Report

Edison Investment Research

Sean Conroy

Cantargia - Encouraging data for nadunolimab in CANFOUR

Cantargia has presented new data from the Phase I/IIa CANFOUR trial at the American Association for Cancer Research (AACR) 2023 meeting. This included an interim analysis of patients (n=73) with pancreatic cancer (PDAC) receiving nadunolimab (an IL1RAP-targeting antibody) in combination with chemotherapy. Superior efficacy was observed in nadunolimab-treated patients relative to historical data of chemotherapy alone (median overall survival (mOS) of 12.9 months versus 8.5 months). Deeper and more durable responses were also reported in the ‘IL1RAP high’ subgroup relative to the ‘IL1RAP low’ subgroup (mOS of 14.2 months versus 10.6 months). We believe these data are encouraging for nadunolimab as a potential first-line treatment for PDAC, especially for patients with high levels of IL1RAP, given that IL1RAP expression was associated with greater treatment responses in several measures.

19/04/2023 1 EN

Underlying

Cantargia AB

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

See profile

SE0006371126 Nasdaq Nordic Stockholm Sweden

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

Cantargia AB: 5 directors

Five Directors at Cantargia AB bought 69,963 shares at between 3.297SEK and 3.402SEK. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules....

Free Trial

January 19, 2024 January 19, 2024 1 EN

Edison Investment Research

Cantargia - First patient treated in Phase II part of TRIFOUR

Cantargia is a clinical-stage biotechnology company with lead asset nadunolimab (CAN04) under assessment for several oncology indications. The company has announced that the first triple-negative breast cancer patient has been treated in the Phase II part of the TRIFOUR trial. The Phase Ib portion showed a favourable safety profile of the drug with early signs of efficacy. The Phase II portion is an open-label, randomised trial to compare nadunolimab in combination with chemotherapy agents gemcitabine and carboplatin against the chemotherapy agents alone (expected n=98). We view this as an imp...

March 14, 2023 March 14, 2023 1 EN

AUSTRIACARD - Solid Q324 supports FY24 outlook

AUSTRIACARD’s Q324 results confirmed the company made good progress towards its FY24 adjusted revenue and EBITDA targets. The sale of metal cards to banks, a new security printing contract in East Africa and a growing number of digital transformation projects helped generate adjusted revenue growth of 30% y-o-y in Q324 and 14% in the first nine months of 2024 (9M24). Adjusted operating profit grew 52% y-o-y in Q324 and 23% for 9M24, with operating margin expansion of 0.7pp to 10.2% for 9M24. With full-year guidance unchanged, we broadly maintain our forecasts.

11h / 19m 11h / 19m 1 EN

Sanjeev Bahl

Sanjeev Bahl

HELLENiQ ENERGY - Margins troughed in Q3, expect Q4 improvement

HELLENiQ ENERGY’s Q324 results were held back by a weak refining environment, as previously guided by the company, but showed an impressive operational performance. The company noted that the Q424 refining margin is likely to be $2/bbl to $3/bbl above the average for Q3. Q3 refining sales volumes of 4.163m tonnes were up 8% y-o-y, adjusted EBITDA of €183m was down 54% y o y and adjusted net income of €49m was down 77% y-o-y. HELLENiQ’s Q324 benchmark refining margin declined to $3.6/bbl, from $5.5/bbl in Q224, as anticipated by the company at the Q2 results, and at its lowest level since 2021....

13h / 29m 13h / 29m 1 EN

Richard Williamson

Richard Williamson

Nanoco Group - Board states case for voting against resolutions

Nanoco has issued a circular recommending that shareholders vote against both resolutions being proposed by Milkwood in its requisition for a general meeting (scheduled for 11:30am on 13 December 2024). We summarise the board’s key arguments below.

17h / 2m 17h / 2m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Cantargia - Encouraging data for nadunolimab in CANFOUR

Cantargia AB: 5 directors

Cantargia - First patient treated in Phase II part of TRIFOUR

AUSTRIACARD - Solid Q324 supports FY24 outlook

HELLENiQ ENERGY - Margins troughed in Q3, expect Q4 improvement

Nanoco Group - Board states case for voting against resolutions

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe